A comparison of tiotropium 18μg, once daily and ipratropium 40μg, 4 times daily in a double-blind, double-dummy, efficacy and safety study in adults with chronic obstructive pulmonary disease

Seung Joon Kim, Myung Sook Kim, Sang Haak Lee, Young Kyoon Kim, Hwa Sik Moon, Sung Hak Park, Sang Yeub Lee, Kwang Ho In, Chang Youl Lee, Young Sam Kim, Hyung Jung Kim, Chul Min Ahn, Sung Kyu Kim, Kyung Rok Kim, Seung Ick Cha, Tae Hoon Jung, Mi Ok Kim, Sung Soo Park, Cheon Woong Choi, Jee Hong YooHong Mo Kang, Won Jung Koh, Hyoung Suk Ham, Eun Hae Kang, O. Jung Kwon, Yang Deok Lee, Heung Bum Lee, Yong Chul Lee, Yang Keun Rhee, Won Hyuk Shin, Sung Yeon Kwon, Woo Jin Kim, Chul Gyu Yoo, Young Whan Kim, Young Soo Shim, Sung Koo Han, Hye Kyung Park, Yun Seong Kim, Min Ki Lee, Soon Kew Park, Mi Hye Kim, Won Yeon Lee, Suk Joong Yong, Kye Chul Shin, Byoung Whui Choi, Yeon Mok Oh, Chae Man Lim, Sang Do Lee, Woo Sung Kim, Dong Soon Kim, Sung Soo Jung, Ju Ock Kim, Young Chun Ko, Young Chul Kim, Nam Soo Yoo

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: This study compared the bronchodilator efficacy and safety of tiotropium inhalation capsules (18μg once daily) with a ipratropium metered dose inhaler (2 puffs of 20μg q.i.d.) in patients with chronic obstructive pulmonary disease (COPD). Method: After the initial screening assessment and a two week run in period, patients received either tiotropium 18μg once daily or ipratropium 40μg four times daily over a period of 4 weeks in a double blind, double dummy, parallel group study. The outcome measures were the lung function, the daily records of the peak expiratory flow rate (PEFR), the patients' questionnaire, and the use of concomitant salbutamol. The forced expiratory volume in one second (FEV1) and the forced vital capacity (FVC) were measured 5 minutes before inhalation, and 0.5, 1, 2 and 3 hours after inhaling the study drug on days 0, 14 and 28. Result: In 16 centers, 134 patients with a mean (SD) age of 66 (7) years and a predicted FEV1 of 42 (12)% were analyzed. The trough FEV1 response was significantly higher in the tiotropium group than in the ipratropium group after a four week treatment period. The weekly mean morning PEFR of the tiotropium group was consistently higher than that of the ipratropium group during the 4 week treatment period with differences ranging from 12.52 to 13.88 l/min, which were statistically significant. Tiotropium was well tolerated by the COPD patients during the 4-week treatment period and had a similar safety profile to ipratropium. Conclusion: This study shows that tiotropium administrated once daily has a superior bronchodilator effect with a similar safety profile in treating COPD patients compared with ipratropium, inhaled four times daily.

Original languageEnglish
Pages (from-to)498-506
Number of pages9
JournalTuberculosis and Respiratory Diseases
Volume58
Issue number5
DOIs
Publication statusPublished - 2005 May

Keywords

  • COPD
  • Efficacy
  • Ipratropium
  • Safety
  • Tiotropium

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Infectious Diseases

Fingerprint Dive into the research topics of 'A comparison of tiotropium 18μg, once daily and ipratropium 40μg, 4 times daily in a double-blind, double-dummy, efficacy and safety study in adults with chronic obstructive pulmonary disease'. Together they form a unique fingerprint.

  • Cite this

    Kim, S. J., Kim, M. S., Lee, S. H., Kim, Y. K., Moon, H. S., Park, S. H., Lee, S. Y., In, K. H., Lee, C. Y., Kim, Y. S., Kim, H. J., Ahn, C. M., Kim, S. K., Kim, K. R., Cha, S. I., Jung, T. H., Kim, M. O., Park, S. S., Choi, C. W., ... Yoo, N. S. (2005). A comparison of tiotropium 18μg, once daily and ipratropium 40μg, 4 times daily in a double-blind, double-dummy, efficacy and safety study in adults with chronic obstructive pulmonary disease. Tuberculosis and Respiratory Diseases, 58(5), 498-506. https://doi.org/10.4046/trd.2005.58.5.498